National Cancer Institutes
Abdul Rafeh Naqash, MD, received his medical degree at Government Medical College Srinagar, Kashmir. He completed his Internal medicine residency training at the University of Buffalo/Catholic Health and his sub-specialty clinical training in Hematology/Oncology at East Carolina University, Greenville, NC. Currently, Dr. Naqash is pursuing an Investigational Cancer Therapeutics fellowship at the National Cancer Institute, Bethesda with a focus on developing phase I/II trials involving novel combinations that include targeted agents, chemotherapies and immunotherapies for patients with advanced solid tumors. Dr. Naqash’s long-term interests revolve around identifying biomarkers of response or resistance to immune checkpoint therapies and evaluating the mechanistic aspects of immune-related adverse events (irAEs) and their clinical outcomes. Dr. Naqash is also a member of Sparkathon class of 2018, a SITC driven young investigator collaborative network working on developing a trial with correlative studies to evaluate the optimal duration of immune checkpoint therapy in melanoma.